CRBU vs. GLUE, CLLS, VXRT, SGMO, BLUE, RGNX, HLVX, EXAI, ITOS, and VALN
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Monte Rosa Therapeutics (GLUE), Cellectis (CLLS), Vaxart (VXRT), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), REGENXBIO (RGNX), HilleVax (HLVX), Exscientia (EXAI), iTeos Therapeutics (ITOS), and Valneva (VALN). These companies are all part of the "biological products, except diagnostic" industry.
Caribou Biosciences (NASDAQ:CRBU) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
In the previous week, Caribou Biosciences had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 beat Caribou Biosciences' score of -0.79 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Caribou Biosciences has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -345.05%. Caribou Biosciences' return on equity of -33.42% beat Monte Rosa Therapeutics' return on equity.
Caribou Biosciences received 8 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 52.94% of users gave Caribou Biosciences an outperform vote while only 40.00% of users gave Monte Rosa Therapeutics an outperform vote.
Caribou Biosciences currently has a consensus target price of $15.25, indicating a potential upside of 711.17%. Monte Rosa Therapeutics has a consensus target price of $11.00, indicating a potential upside of 173.63%. Given Caribou Biosciences' higher probable upside, equities analysts clearly believe Caribou Biosciences is more favorable than Monte Rosa Therapeutics.
Caribou Biosciences has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats Monte Rosa Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
